Cancer survivors often encounter a variety of health issues, the most common of which include fatigue, peripheral neuropathy, and depression. To address those specific issues, the American Society of Clinical Oncology (ASCO) has developed 3 new sets of guidelines on cancer survivorship care.
Cancer survivors often encounter a variety of health issues, the most common of which include fatigue, peripheral neuropathy, and depression. To address those specific issues, the American Society of Clinical Oncology (ASCO) has developed 3 new sets of guidelines on cancer survivorship care.
“The recommendations reinforce the need to care for both the physical and psychological needs of cancer survivors,” read an ASCO official statement.
The statement also noted that despite important advances in cancer treatment, cancer survivors “still face a range of long-term challenges from their disease and its treatment.”
The 3 survivorship recommendations belong to a series of 18 clinical practice guidelines that will be released by ASCO. ASCO-convened panels developed the fatigue and neuropathy guidelines, while the depression recommendations were adapted from Canadian-based guidelines.
“Doctors sometimes don’t give these symptoms much attention because they think it’s normal that their patients are a little anxious or depressed about their disease,” said Gary Lyman, MD, MPH, FACP, FRCP (Edin), FASCO, of the Fred Hutchinson Cancer Center in Seattle, and chair of the ASCO Survivorship Guidelines Advisory Committee. “But it’s important to keep an eye on the symptoms and step in when they start to interfere with the patient’s quality of life.”
The newly developed guidelines seem to answer a call to action from the American Cancer Society in 2012. It emphasized the increasing importance of understanding the medical and psychosocial needs of patients and providers as they go through the various phases of cancer survivorship. Crystal Denlinger, MD, an oncologist at Fox Chase Cancer Center in Philadelphia, Pennsylvania, even seemed to predict the emergence of such guidelines in a 2013 article published in Evidence-Based Oncology, a publication of The American Journal of Managed Care.
“The survivorship care plan that delineates what is required for follow-p has gained a lot of traction,’’ she said. “A lot of people are struggling with how to put together these care plans when, for many patients, the information is scattered across multiple offices and multiple systems.’’
The guidelines are available on the ASCO website.
Around the Web
New Guidelines Address Cancer Survivors' Issues [MedPage Today]
The Quest for Better Survivorship: Guidelines Promote More Accountable Cancer Care [AJMC]
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
March 17th 2025As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.
Read More
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More